Skip to main content

DUPIXENT IS THE FIRST AND ONLY FDA-APPROVED DUAL INHIBITOR of
IL-4 and IL-13 Signaling, TWO OF THE Key Drivers of Type 2 Inflammation1,a

select a condition

Uncontrolled Moderate-to-Severe

Atopic Dermatitis

For Patients Ages 6+ Months

Chronic Spontaneous
Urticaria

For Patients Ages 12+ Years Who Remain
Symptomatic Despite H1 Antihistamine
Treatment

Limitations of Use: DUPIXENT is not indicated for
other forms of urticaria.

Prurigo Nodularis

For Patients Ages 18+ Years

Add-on Maintenance for Moderate-to-Severe

Asthma

For Patients Ages 6+ Years With an
Eosinophilic Phenotype or OCS
Dependent

Limitations of Use: DUPIXENT is not indicated for the
relief of acute bronchospasm or status asthmaticus.

Add-on Maintenance for Inadequately Controlled

Chronic Obstructive
Pulmonary Disease

For Patients Ages 18+ Years With an
Eosinophilic Phenotype

Limitations of Use: DUPIXENT is not indicated for the
relief of acute bronchospasm.

Add-on Maintenance for Inadequately Controlled

Chronic Rhinosinusitis
with Nasal Polyps

For Patients Ages 12+ Years

Eosinophilic Esophagitis

For Patients Ages 1+ Years,
Weighing at Least 15 kg

PATIENTS ON THERAPY ACROSS
APPROVED INDICATIONS WORLDWIDE2,b

aThe mechanism of dupilumab action has not been definitively established.

bThis worldwide number is largely comprised from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, the UK, and the US), with the rest of the world comprising ≈10% of this number. This number is comprised of the following US approved indications: AD, asthma, CRSwNP, PN, and EoE. Data through February 2025.

Dupixent® (dupilumab) 200mg and 300mg pre-filled pen and syringe packaging

Dosing & Administration

DUPIXENT offers 2 administration options: the pre-filled
pen (indicated ages 2+ years) and the pre-filled syringe
(indicated ages 6+ months). Both options are available in
200 mg and 300 mg doses and can be self-administered
at home (after proper training by a healthcare provider)
or administered in your office.

Moderate‑to‑Severe
Asthma

Moderate‑to‑Severe Atopic
Dermatitis

Chronic Obstructive Pulmonary Disease

Chronic Rhinosinusitis with
Nasal Polyps

Chronic Spontaneous Urticaria

Eosinophilic Esophagitis

Prurigo Nodularis

dosing

ENROLL YOUR PATIENTS
IN DUPIXENT MyWay®

DUPIXENT MyWay is a patient support program that can
help your patients access DUPIXENT and find support
throughout their treatment journey. Download and fill out
the enrollment form with your patients.

CHOOSE CONDITION

Moderate-to-Severe Asthma

Moderate-to-Severe Atopic Dermatitis

Chronic Obstructive Pulmonary Disease

Chronic Rhinosinusitis with Nasal Polyps

Chronic Spontaneous Urticaria

Eosinophilic Esophagitis

Prurigo Nodularis

DUPIXENT MyWay ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

DUPIXENT MyWay ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

DUPIXENT MyWay ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

DUPIXENT MyWay ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

DUPIXENT MyWay ENROLLMENT FORMS
English Enrollment Form

DUPIXENT MyWay ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

DUPIXENT MyWay ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

QUESTIONS ABOUT DUPIXENT MyWay?

Call 1-844-DUPIXEN(T)
(1-844-387-4936), option 1
Monday-Friday, 8 am to 9 pm ET

Or click below to learn more:

LEARN ABOUT DUPIXENT MyWay
Contact a Representative

Speak to a live representative who can answer questions about clinical data, dosing, and more.

CONTACT us